New combo therapy aims to shrink HER2+ stomach tumors before surgery
NCT ID NCT06731803
First seen Mar 23, 2026 · Last updated Jun 17, 2026 · Updated 11 times
Summary
This study tests whether combining the targeted drug trastuzumab-deruxtecan with other treatments before surgery is safe and feasible for people with HER2-positive stomach or esophagus cancer that has not spread. About 36 adults will receive the drug combinations before their planned surgery. The goal is to see if the treatment can be given as planned without serious side effects, and to measure how well it controls the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGOGASTRIC ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Charite Universitätsmedizin Berlin
Berlin, 13353, Germany
-
Hämatologisch-Onkologische Praxis Eppendorf (hope)
Hamburg, 20249, Germany
-
KEM | Kliniken Essen Mitte gGmbH Klinik für Internistische Onkologie / Hämatologie mit Integrierter Palliativmedizin
Essen, 45136, Germany
-
Klinikum Chemnitz gGmbH
Chemnitz, 09116, Germany
-
Klinikum Nürnberg
Nuremberg, 90419, Germany
-
Klinikum rechts der Isar München der TU München
München, 81675, Germany
-
Krankenhaus Nordwest GmbH Institut für Klinisch-Onkologische Forschung (IKF)
Frankfurt am Main, 60488, Germany
-
Medizinische Universität Wien, Universitätsklinik für Innere Medizin I
Vienna, 1090, Austria
-
Nationales Centrum für Tumorerkrankungen
Heidelberg, 69120, Germany
-
Uniklinikum Salzburg, Universitätsinstitut für Innere Medizin III der PMU
Salzburg, 5020, Austria
-
Universitätsklinikum Jena
Jena, 07747, Germany
-
Universitätsklinikum Leipzig
Leipzig, 04103, Germany
-
Universitätsklinikum Ulm
Ulm, 89081, Germany
-
Universitätsmedizin Halle, Universitätsklinikum Halle (Saale)
Halle, 06120, Germany
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.